Evaluation of mucoadhesive nanoparticle based nasal vaccine

Journal of Pharmaceutical Investigation

Volumn 42, Issue 6, 2012, Pages 315-326

  Krishnakumar, D ^a,b   Kalaiyarasi, D ^c   Bose, J C ^c   Jaganathan, K S ^c  

^a Erode College of Pharmacy   (India)

^b Shantha Biotechnics Ltd   (India)

^c JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Chitosan; Hepatitis B surface antigen; Nanoparticles; Nasal vaccine; PLGA; Trimethyl chitosan

Indexed keywords

CHITOSAN; HEPATITIS B SURFACE ANTIGEN; MUCIN; NANOPARTICLE; NASAL VACCINE; POLYGLACTIN; UNCLASSIFIED DRUG; VACCINE;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN STRUCTURE; ARTICLE; CILIARY MOTILITY; COLORIMETRY; CONFOCAL MICROSCOPE; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOGENICITY; LUNG ALVEOLUS MACROPHAGE; MALE; MOUSE; MUCOADHESION; NONHUMAN; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; TOXICITY; ZETA POTENTIAL;

EID: 84876518896     PISSN: 20935552     EISSN: 20936214     Source Type: Journal    
DOI: 10.1007/s40005-012-0042-3     Document Type: Article

References (43)

1. Almeida AJ, Alpar HO (1996) Nasal delivery of vaccines. J Drug Target 3: 455-467.
2. Baca-Estrada ME, Foldvari M, Snider M (1999) Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. J Interferon Cytokine Res 19: 455-462.
3. Bal SM, Slütter B, van Riet E, Kruithof AC, Ding Z, Kersten GF (2009) Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. J Control Release 142: 374-383.
4. Bowman K, Leong KW (2006) Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomed 1(2): 117-128.
5. Brandtzaeg P (2011) Potential of nasopharynx-associated lymphoid tissue for vaccine responses in the airways. Am J Respir Crit Care Med 183: 1595-1604.
6. Chandan T, Vivek G, Fakhrul A (2010) Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles. Pharma Res 27(5): 905-919.
7. Cruz LF, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F, Torensma R, Figdor CG et al (2010) Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release 144(2): 118-126.
8. Debin A, Kravtzoff R, Santiago JV, Cazales L, Sperandio S, Melber K (2002) Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine 20: 2752-2763.
9. Dilip P, Amit KG, Sharad M, Neeraj M, Bhuvaneshwar V, Shailja T, Arvind KJ, Suresh PV (2010) Evaluation of mucoadhesive PLGA microparticles for nasal immunization. AAPS J 12(2): 130-137.
10. Elamanchili P, Diwan M, Cao M, Samuel J (2004) Characterization of poly(d, l,-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22(19): 2406-2412.
11. Espuelas S, Gamazo C, Balnco-Prieto MJ, Irache JM (2007) Nanoparticles as adjuvant-vectors for vaccination in nanoparticulate drug delivery systems. Informa Healthc 166: 317.
12. Evora C, Soriano I, Rogers RA, Shakesheff KN, Hanes J, Langer R (1998) Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1, 2-dipalmitoylphosphatidylcholine. J Control Release 51: 143-152.
13. Fiebrig I, Harding SE, Rowe AJ, Hyman SC, Davis SS (1995) Transmission electron microscopy studies on pig gastric mucin and its interactions with chitosan. Carbohydr Polym 28(3): 239-244.
14. Filipović-Grčić J, Škalko-Basnet N, Jalšienjak I (2001) Mucoadhesive chitosan-coated liposomes: characteristics and stability. J Microencapsul 18(1): 3-12.
15. Fischer S, Uetz-von Allmen E, Waeckerle-Men Y, Groettrup M, Merkle HP, Gander B (2007) The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 28: 994-1004.
16. Friede M, Aguado MT (2005) Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems. Adv Drug Deliv Rev 57: 325-331.
17. Gupta RK, Siber GR (1995) Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 13: 1263-1276.
18. Gutierro I, Pedraz JL (2002) Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 21: 67-77.
19. Jaganathan KS, Suresh PV (2006) Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant Hepatitis B antigen administered intranasally. Vaccine 24: 4201-4211.
20. Jain S, Singh P, Mishra V, Vyas SP (2005) Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against Hepatitis B. Immunol Lett 101(1): 41-49.
21. Jorissen M, van der Schueren B, Tyberghein J, van der Berghe H, Cassiman JJ (1989) Ciliogenesis and coordinated ciliary beating in human nasal epithelial cells cultured in vitro. Acta Otorhinolaryngol Belg 43: 67-73.
22. Jung T, Kamm W, Breitenbach A, Hungerer KD, Hundt E, Kissel T (2001) Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm Res 18: 352-360.
23. Kaliner M, Shelhamer JH, Borson B, Nadel J, Patow C, Marom Z (1986) Human respiratory mucus. Am Rev Respir Dis 134: 612-621.
24. Kanchan V, Panda AK (2007) Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 28(35): 5344-5357.
25. Kiyono H, Fukuyama S (2004) NALT versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 4: 699-710.
26. Kotzé AF, Thanou MM, Lueben HL, De Boer AG, Coos Verhoef J, Junginger HE (1998) Enhancement of paracellular drug transport with highly quaternized N-Trimethyl chitosan chloride in neutral environments: In vitro evaluation in intestinal epithelial cells (Caco-2). J Pharm Sci 88(2): 253-257.
27. Kwon YJ, Standley SM, Goh SL, Fréchet JMJ (2005) Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. J Control Release 105: 199-212.
28. Lehr C-M, Bouwstra JA, Schacht EH, Junginge HE (1992) In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 78(1-3): 43-48.
29. Lemoine D, Deschuyteneer M, Hogge F, Preat V (1999) Intranasal immunization against influenza virus using polymeric particles. J Biomater Sci Polym Ed 10: 805-825.
30. Panyam J (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55: 329-347.
31. Peppas NA, Carr DA (2009) Impact of absorption and transport on intelligent therapeutics and nanoscale delivery of protein therapeutic agents. Chem Eng Sci 64: 4553-4565.
32. Sayin B, Somavarapu S, Li XW, Thanou M, Sesardic D, Alpar HO (2008) Mono-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int J Pharm 363: 139-148.
33. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP (2006) Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28: 112-125.
34. Slütter B, Plapied L, Fievez V, Alonso Sande M, des Rieux A, Schneider YJ (2009) Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release 138: 113-121.
35. Somavarapu S, Alpar HO, Song CYS (1998) Biodegradable nanoparticles in nasal vaccine delivery: effect of particle size and loading. Proc Int Symp Control Release Bioact Mater 25: 645-646.
36. Sun H, Pollock KG, Brewer JM (2003) Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21: 849-885.
37. Takada S, Yamagata Y, Misaki M, Taira K, Kurokawa T (2003) Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique. J Control Release 88: 229-242.
38. Takeuchi H, Yamamoto H, Kawashima Y (2001) Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47(1): 39-54.
39. Thiele L, Merkle HP, Walter E (2002) Phagocytosis of synthetic particulate vaccine delivery systems to program dendritic cells. Expert Rev Vaccines 1: 215-226.
40. Thomas C, Gupta V, Ahsan F (2010) Particle size influences the immune response produced by Hepatitis B vaccine formulated in inhalable particles. Pharm Res 27(5): 905-919.
41. Vajdy M, O'Hagan DT (2001) Microparticles for intranasal immunization. Adv Drug Deliv Rev 51: 127-141.
42. Vila A, Sanchez A, Evora C, Soriano I, McCallion O, Alonso MJ (2005) PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int J Pharm 292: 43-52.
43. Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, Plebanski M (2006) Pathogen recognition and development of particulate vaccines: does size matter? Methods 40: 1-9.